Gout

RheumNow Podcast – with Special Guest Dr. Kathryn Dao (9.29.2023)

Save

Jack Cush, MD

Sep 29, 2023

This week on the podcast, Dr. Jack Cush is joined by special guest, Dr. Kathryn Dao to review the news and journal reports from the past week on RheumNow.com. They discuss unmet needs in gout, obesity and CV disease in PsA and should you check ANCA antibodies in SLE?

Painful

Read Article

What Changed FDA's Mind About Ilaris for Gout?

Save

MedPage Today

Sep 21, 2023

The FDA quietly approved the interleukin (IL)-1 inhibitor canakinumab (Ilaris) for gout 10 days ago, with no announcement from either the agency or the drug's manufacturer, Novartis -- leaving outsiders to guess at what changed in the dozen years since the company's first attempt to gain

Read Article

Full read review of Colchicine drug interactions - primarily inhibitors of CYP3A4 (includes statins, amiodarone, cyclosporine, voriconazole). Signs of colchicine toxicity include diarrhea, myalgia, weakness, myoglobinuria, BM suppression/cytopenias. https://t.co/qddOnCJc5x https://t.co/2yGlr4nXmF

RheumNow @Dr. John Cush( View Tweet )

Sep 09, 2023

SAVE THE DATE! RheumNow Live will now be taking place in January! Who is joining us? https://t.co/EdrLp87Z81

RheumNow @Dr. John Cush( View Tweet )

Sep 09, 2023

RheumNow Podcast – with Special Guest Dr. Janet Pope (9.8.2023)

Save

Jack Cush, MD

Sep 08, 2023

This week, Dr. Jack Cush reviews the news with special guest, Dr. Janet Pope. They discuss "Not-non-Inferior", large scale genetic screening, Zoster risk w/ newer lupus drugs, tapering, RA referral problems and the TNR webinar session on "ORAL Surveillance Revisited".

Read Article

Placebo is not non-inferior to colchicine in gout flare prevention in 1st 6 mos of allopurinol. 200 pts, Gout flares - 0.61 PBO vs 0.35 Colchicine. After stopping colchicine, no difference ingout flares/month between groups over 12-mos https://t.co/hYvAKtqPbA https://t.co/rnRiz9cKlu

RheumNow @Dr. John Cush( View Tweet )

Sep 05, 2023

FDA Approves Canakinumab for Gout Flares The US FDA has approved canakinumab (Ilaris) for the treatment of gout flares in adults who cannot be treated with NSAIDs, colchicine, or repeated courses of corticosteroids. https://t.co/0IV1V31LJm https://t.co/oua0F9b7Jb

RheumNow @Dr. John Cush( View Tweet )

Sep 03, 2023

SGLT2 Inhibitors as Gout Treatment Patients with gout and type 2 diabetes treated with SGLT2 inhibitors not only had reduced numbers of gout flares, but also lived longer compared with other such patients receiving other medications, researchers said. https://t.co/mNale47A38 https://t.co/AeskZCfSaJ

RheumNow @Dr. John Cush( View Tweet )

Sep 03, 2023

Hard Decisions in RA (9.1.2023)

Save

Jack Cush, MD

Sep 01, 2023

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow, and introduces our September campaign - "Hard Decisions in RA".

Read Article

SAVE THE DATE! RheumNow Live will now be taking place in January! Will you be there? https://t.co/WCfBzthXvl

RheumNow @Dr. John Cush( View Tweet )

Aug 31, 2023

FDA Approves Canakinumab for Gout Flares

Save

Medscape

Aug 30, 2023

The US Food and Drug Administration (FDA) has approved canakinumab (Ilaris) for the treatment of gout flares in adults who cannot be treated with NSAIDs, colchicine, or repeated courses of corticosteroids. The drug is also indicated for people who could not tolerate or had an inadequate response

Read Article

SGLT2 Inhibitors as Gout Treatment

Save

MedPage Today

Aug 30, 2023

Patients with gout and type 2 diabetes treated with SGLT2 inhibitors not only had reduced numbers of gout flares, but also lived longer compared with other such patients receiving other medications, researchers said.

Read Article

Data from Korean KNHANES survey shows Hyperuricemia OR:1.41 (but not gout) is independently assoc w/ hearing impairment, especially in females & > 60 yrs. https://t.co/PkzLk526Bi https://t.co/WePaJ2hltW

RheumNow @Dr. John Cush( View Tweet )

Aug 28, 2023

Taiwan Health records research show gout (121,236) patients, when propensity matched (121,236) w/ control, finds gout pts have a signif risk of abd aortic aneurysm (HR= 2.46); that was cut in half with ULR (adjHR= 0.49) https://t.co/ijOBHAwTr3 https://t.co/pOZRzWGTsL

RheumNow @Dr. John Cush( View Tweet )

Aug 27, 2023

Did you know that gout can affect the vocal cords? https://t.co/0SjVZ6sgjx https://t.co/RlmCaIyO2D

drkeithsiau @Keith Siau( View Tweet )

Aug 25, 2023

Pizza and Rheumatoid Arthritis (8.11.2023)

Save

Jack Cush, MD

Aug 11, 2023

Dr. Jack Cush reviews the news and journal reports from the wonderful wide world of Rheumatology. This week:

Swedish study of 325 #AAV pts saw CVA in 35 pts (8%); CVA incidence=11.3/1000 PYs - this was higher than gen population [SIR 1.85). AAV CVA risk factors included age

Read Article

Patient Perspectives on Telemedicine Use During the Pandemic Research from the COVID-19 Global Rheumatology Alliance included surveys and data gathering from rheumatology patients. https://t.co/EJ5TkiDMcJ https://t.co/xBx7OIxf9h

Links:

https://bit.ly/45lemA9

Dr. John Cush @RheumNow( View Tweet )

Aug 10, 2023

Colchicine or Prednisone in CPPD?

Save

Jack Cush, MD

Aug 09, 2023

The COLCHICORT trial in patients with acute calcium pyrophosphate crystal arthritis (CPPD) demonstrated equivalent efficacy for both colchicine and prednisone, yet different safety signals were seen.

Read Article

NHANES study of >204 million persons finds 19.6% w/ hyperuricemia (HUC) & 4.1% w/ gout. Gout/HUC pts had higher tisk (HR 2.4) of heart failure (HF), expecially w/ age, DM, CV, & CAD risk factors, & w/ HF, 5-yr survival was 59.9% & 55.9% (1.4x ^ mortality) https://t.co/IrAUHcOV85 https://t.co/2AWhMES28g

Links:

https://bit.ly/44VXmR3

Dr. John Cush @RheumNow( View Tweet )

Aug 08, 2023

HEALTH DISPARITIES: Lancet study shows from 2000-2019, all-cause mortality was signif. higher in the American Indian/Alaska Native (1028/100K) & Blacks (953·/100K) compared to Whites (802); but lower in Asians (442) & Latinos (595) https://t.co/g8Z3h6BYw8 https://t.co/Ckz1L3O0W7

Links:

https://bit.ly/45eZ67L

Dr. John Cush @RheumNow( View Tweet )

Aug 04, 2023

Rheums: Have a rheumatology question or case for Dr. Cush? Record it here and we'll feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/uY9Mwyrsn3

Links:

https://bit.ly/47dWEQJ

Dr. John Cush @RheumNow( View Tweet )

Aug 03, 2023

2023 ACR/EULAR Criteria for Calcium Pyrophosphate Deposition Disease

Save

Jack Cush, MD

Jul 27, 2023

The prevalence of radiographic chondrocalcinosis is estimated to be 4% to ≥10% in older adults, but the prevalence of symptomatic calcium pyrophosphate deposition (CPPD) disease is unknown. To advance our understanding of CPPD, the American College of Rheumatology and EULAR have published

Read Article

UK-NiCE Guidelines on Gout: Treat to Target to Prevent Irreparable Joint Damage Indications for Urate-lowering Rx: - Multiple/troublesome flares - CKD 3 to 5 - Diuretic Rx - Tophi - Chronic gouty arthritis https://t.co/eUqQpn7QUI https://t.co/eAGTRShYlf

Links:

https://bit.ly/455I8ZF

Dr. John Cush @RheumNow( View Tweet )

Jul 27, 2023

IL-1β inhibitors can be effective in #Gout. Based on metanalysis of 14 studies(10 RCTs), 4367 gout pts (Rx w/ anakinra, canakinumab rilonacept) Shows CAN, RIL better than active comparator at pain; CAN/RIL reduced gout flares https://t.co/57JSFtLLJD https://t.co/RueDE01jHj

Links:

https://bit.ly/44JdOEn

Dr. John Cush @RheumNow( View Tweet )

Jul 27, 2023

SGLT2 Inhibitors Reduce Gout Flares and CV Events A cohort analysis shows that gout patients initiating sodium–glucose cotransporter-2 inhibitors (SGLT2is) had lower serum urate levels and fewer gouty flares requiring ED visits or hospitalizations. https://t.co/fmz1j6pHgL https://t.co/XbqWxZRd97

Links:

https://bit.ly/44Gkvah

Dr. John Cush @RheumNow( View Tweet )

Jul 26, 2023

Recent Blogs

A Brief History of Rheumatoid Arthritis Mimics

Save

Robert Schoen, MD, MBA

Sep 06, 2023

Imagine that 100 years from now, your great granddaughter, an eminent rheumatologist, reviews the history of rheumatoid arthritis mimics. Read Post

From the Archives: Rheumatology Dead Word Cemetery

Save

Jack Cush, MD

Oct 31, 2022

I recently heard of a secondary school assignment wherein students were challenged to “bury” a word that was no longer useful or appropriate. Their exercise has now evolved into an unofficial RheumNow task force to retire diagnostic terms that have grown into misuse in rheumatology and medicine. How did we decide which words should perish? And by what criteria? Who has the final say? Read Post